U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new investigational drug for cannabis withdrawal syndrome.

Close up of hands of scientists dropping marijuana oil for experimentation and research.
getty
Pharmaceutical development company PleoPharma has received a grant from the U.S. Federal Drug Administ…